The FDA has approved changes to the wording of the cardiovascular risk reduction indications for the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab (Repatha) and alirocumab (Praluent). Both drugs are now approved to reduce the risk of major adverse cardiovascular events (MACE) in adults at increased risk for these events; they were previously approved to reduce the risk of MACE only in patients with established cardiovascular disease (CVD).
PCSK9 INHIBITORS — Evolocumab and alirocumab are subcutaneously injected monoclonal antibodies that bind to PCSK9...
ISSUE
After 53 years of dedicated service, Mark Abramowicz, M.D., President of The Medical Letter, will retire at the end of 2025.
Dr. Abramowicz joined The Medical Letter in 1972 as Editor, carrying forward the mission established by founders Arthur Kallet and Dr. Harold Aaron: to provide independent, unbiased evaluations of new pharmaceuticals and new indications for previously approved drugs.
A pediatrician by training and a journalist at heart, Dr. Abramowicz’s career has always reflected his passion for medicine and clear communication. Before joining The Medical Letter, he trained at Boston City Hospital, served as a Captain in the U.S. Army Medical Corps, and was a full-time member of the Department of Pediatrics at the Albert Einstein College of Medicine.
Over the past decade, Dr. Abramowicz has worked closely with Jean-Marie Pflomm, Pharm.D., Editor-in-Chief, to ensure a smooth transition. Dr. …